. Author manuscript; available in PMC: 2013 Jan 1.

Published in final edited form as: Trends Pharmacol Sci. 2011 Oct 17;33(1):28–34. doi: 10.1016/j.tips.2011.09.002

Table 1.

Effects of Rab1 wild-type, Rab1 mutants, and siRNA-mediated knockdown of Rab1 on the cell-surface expression of GPCRs

GPCRs	Wild-type	Mutants	siRNA	Cells	Refs
α_1A-AR	↑ ^a	↓ ^a	ND	NRVM	[14]
α_1B-AR	↑ ^a	↓ ^a	↓ ^b	NRVM	[14]
α_2B-AR	– ^b	– ^b	– ^b	HEK293	[15]
β₁-AR	– ^a	↓ ^a	ND	NRVN	[14]
	– ^a	↓ ^a	ND	PMVEC	[16]
β₂-AR	– ^b	↓ ^b	↓ ^b	HEK293	[15,17]
	– ^a	↓ ^a,^b	↓ ^b	NRVM	[14]
	↑ ^a,^b	↓ ^a,^b	↓ ^a,^b	PMVEC	[16]
AT1R	– ^b	↓ ^b	↓ ^b	HEK293	[15]
	ND	↓ ^b	ND	HL-1 myocytes	[18]
	↑ ^a	↓ ^a,^b	ND	NRVM	[18]
	↑ ^a	ND	↓ ^a,^b	PASMC	[19]
AT2R	↑ ^b	↓ ^b	↓ ^b	HEK293	[20]
hCaR	↑ ^b	↓ ^b	ND	HEK293	[21]

↑, increase; ↓, decrease; , no effect; ND, not determined;

endogenous receptors;

exogenous receptors;

PMVEC, pulmonary microvascular endothelial cells; PASMC, pulmonary arterial smooth muscle cells; NRVM, neonatal rat ventricular myocytes.